Search

Indivior PLC

Ouvert

1,242

Résumé

Variation du prix de l'action

24h

Actuel

Min

1242

Max

1242

Chiffres clés

By Trading Economics

Revenu

-19M

47M

Ventes

-33M

266M

P/E

Moyenne du Secteur

330

38.156

Marge bénéficiaire

17.669

Employés

1,030

EBITDA

-30M

76M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+10.23% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

721M

1.5B

Ouverture précédente

1242

Clôture précédente

1242

Indivior PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

31 juil. 2025, 23:56 UTC

Actions en Tendance

Stocks to Watch: Amazon, Bio-Rad, Coinbase, Mercer

31 juil. 2025, 23:48 UTC

Market Talk

Scentre Can Beat Annual Earnings Guidance -- Market Talk

31 juil. 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over Earnings, Domestic Politics -- Market Talk

31 juil. 2025, 23:37 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

31 juil. 2025, 23:37 UTC

Market Talk

Gold Steady as Traders Eye Tariff-Deal Developments -- Market Talk

31 juil. 2025, 23:12 UTC

Résultats

OCBC: Evolving Trade, Monetary Policies, Persistent Geopolitical Tensions Expected to Weigh on Growth Prospects >O39.SG

31 juil. 2025, 23:10 UTC

Résultats

Oversea-Chinese Banking: Declining Interest-Rate Environment Weighed in Net Interest Income >O39.SG

31 juil. 2025, 23:09 UTC

Résultats

Oversea-Chinese Banking 2Q Net Interest Income S$2.28B Vs. S$2.43B >O39.SG

31 juil. 2025, 23:08 UTC

Résultats

Oversea-Chinese Banking 2Q Total Income S$3.55B Vs. S$3.63B >O39.SG

31 juil. 2025, 23:08 UTC

Résultats

Oversea-Chinese Banking 2Q Net S$1.82B Vs. Net S$1.94B >O39.SG

31 juil. 2025, 23:01 UTC

Résultats

Amazon Posts Higher Sales, Profit -- 3rd Update

31 juil. 2025, 22:08 UTC

Market Talk
Résultats

Amazon CEO Impressed by Deals Signed for Project Kuiper -- Market Talk

31 juil. 2025, 22:02 UTC

Market Talk
Résultats

Apple's FY Outlook Shows Sales Growth Won't Last -- Market Talk

31 juil. 2025, 21:57 UTC

Market Talk
Résultats

Amazon CEO Sees Strong Early Demand for Alexa+ -- Market Talk

31 juil. 2025, 21:50 UTC

Résultats

Amazon Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

31 juil. 2025, 21:43 UTC

Résultats

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- 2nd Update

31 juil. 2025, 21:29 UTC

Résultats

Amazon to Invest More in Chips, Data Centers Amid Generative AI Opportunity, CFO Says

31 juil. 2025, 21:26 UTC

Résultats

Apple Expects Revenue to Grow in Mid- to High-Single Digits in Current Quarter, CFO Says

31 juil. 2025, 21:26 UTC

Résultats

MicroStrategy Beats Earnings Estimates. The Stock Rises. -- Barrons.com

31 juil. 2025, 21:22 UTC

Résultats

Amazon Has Impressive Amount of Agreements for Project Kuiper, CEO Says

31 juil. 2025, 21:19 UTC

Résultats

Apple Estimates Tariff Impact to Add $1.1B to Costs in Current Quarter, CEO Says

31 juil. 2025, 21:19 UTC

Résultats

Apple Incurred $800M in Tariff-Related Costs in 2Q, CEO Says

31 juil. 2025, 21:14 UTC

Résultats

Amazon's AWS is Seeing More Demand Than Supply, CEO Says

31 juil. 2025, 21:12 UTC

Résultats

Amazon Saw Record Prime Sign-Ups in 3 Weeks Before Prime Day, CEO Says

31 juil. 2025, 21:10 UTC

Résultats

Amazon Just Getting Started on Automation, Robotics to Boost Efficiency, CEO Says

31 juil. 2025, 21:09 UTC

Résultats

Amazon Delivered to Prime Members at Record Pace in 2Q, CEO Says

31 juil. 2025, 21:09 UTC

Résultats

Amazon CEO Sees Diversity of Sellers as Advantage for Inflation-Weary Consumers

31 juil. 2025, 21:08 UTC

Résultats

Apple iPhone Revenue Performance Driven by Popularity of iPhone 16 Family, CEO Says

31 juil. 2025, 21:08 UTC

Résultats

Amazon CEO Sees Strong Customer Adoption of Perishables Same-Day Delivery Pilot

31 juil. 2025, 21:05 UTC

Résultats

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- Update

Indivior PLC prévision

Objectif de Prix

By TipRanks

10.23% hausse

Prévisions sur 12 Mois

Moyen 1,364.65 GBX  10.23%

Haut 1,637.581 GBX

Bas 967.662 GBX

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Éléments financiers

$

À Propos Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
help-icon Live chat